Xybion Corporation, leading provider of preclinical R&D solutions announced today that CTI Biotechnology in Suzhou, China has implemented Xybion's Pristima® 7 Preclinical Suite. Pristima® was selected after an exhaustive evaluation of top selling preclinical software systems on the market. Pristima's unique, end-to-end solution for the management of preclinical data from compound receipt through study submission stands apart from its competitors and will serve as the foundation for the CTI's rapid expansion.
CTI Biotechnology is one of the newest and largest preclinical institutions in China and a leading provider of drug development services. To support its expansion efforts in conducting GLP studies, CTI has leveraged Pristima's full capabilities including Colony Management, General Toxicology, Repro Toxicology, Clinical Pathology and Pathology modules, along with Xybion's standard validation package. With the use of Xybion's validation package, training and installation services, CTI has completed a full implementation project in record time.
Located in Kunshan New and High-Tech Development Zone, the facilities of CTI Biotechnology (Suzhou) covers 46700 sqm. The laboratory is designed to international Good Laboratory Practice (GLP) standards and relevant state regulatory requirements and equipped with advanced scientific instruments equipment covering researches in toxicology, pathology, clinical testing, analytical testing and related fields. Pristima was carefully selected to provide the automation and scalability to support a fast-growing organization that is dedicated to continuous improvements in productivity and quality while reducing the labor and time to generate the final report for submission.
Dr. Li Wang, Director of CTI Biotechnology stated that "there were great expectations both functionality and speed of validation for Pristima. Given the ambitious project timelines to implement Pristima and incorporate it as a key component of our GLP business, it was important to have both the validation support and product quality to accomplish this project. We found that Pristima was a great match for our needs and have performed the implementation according to our aggressive plans." Dr. Wang added, "We have developed a very comfortable working relationship with Xybion."
With over 4000 licensed users in Preclinical Laboratories in 14 different countries on 5 continents, Pristima is the most modern and flexible enterprise data management system for safety assessment; facilitating the user compliance by supporting the user's native language for data entry and generating reports in either the native language or in English.
Xybion's CEO Dr. Pradip Banerjee commented, "We are very excited to add CTI Biotechnology to our growing global family of Pristima clients and we work continuously to make Pristima the solution-of-choice within the China market and we are doing so by combining the most feature-rich solution with high quality product services on a 24 hour basis."
Breakthrough in antigen recognition: TRACeR-I enhances immune targeting